Form 4: Arrowhead CMO Sells 15,000 Shares via Pre-Arranged Plan

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, sold 15,000 shares of common stock at $25 per share through a pre-arranged 10b5-1 trading plan.

Summary

• James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), disposed of 15,000 shares of common stock.
• The transaction occurred on September 2, 2025, with shares sold at a price of $25 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Hamilton.
• Following this transaction, Mr. Hamilton beneficially owns 247,122 shares of common stock directly.
• The reported beneficial ownership includes shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic trading, making it a routine financial event for the executive rather than a strong signal about company prospects.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which indicates the transaction was scheduled in advance and not based on immediate, undisclosed material information, thereby reducing concerns about opportunistic insider selling.

Negatives

• An insider sale, even if pre-planned, can sometimes be interpreted by investors as a signal of an insider's reduced confidence in the company's near-term stock price appreciation, particularly from a key executive like the Chief Medical Officer.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's operational or financial performance. The transaction itself reflects a pre-planned financial strategy by the insider.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Industry Context

Insider transactions, particularly sales, are a routine part of executive compensation and personal financial planning. The use of a 10b5-1 plan is a common practice among corporate insiders to sell shares systematically and mitigate concerns about trading on material non-public information, aligning with regulatory compliance and corporate governance best practices.

Stakeholder Impact

• Shareholders: May note the insider sale, but the 10b5-1 plan context suggests it's a routine financial management decision rather than a reflection of immediate company performance or outlook.

Key Dates

Keywords

Arrowhead Pharmaceuticals, ARWR, Insider Sale, Form 4, 10b5-1 Plan, Chief Medical Officer, James C. Hamilton, Stock Transaction